Kline Consumer Insight Report
This article was originally published in The Rose Sheet
Executive Summary
Research firm introduces Kline Pulse report "Consumer Insights of Personal Care Innovation 2010," a "ground-breaking" research initiative that gathers authentic consumer insights to help companies make crucial decisions about research and marketing. The first edition of the report offers a glimpse into the nuances of consumer perspectives in personal-care innovation, revealing the underlying attitudes, behaviors, and experiences that drive purchase decisions, Kline says. The scope of the report includes fragrances, hair care, makeup, oral care, skin care and toiletries across various countries. Kline says the approach digs deep into consumer perceptions by avoiding traditional survey techniques such as pre-hypothesizing, categorization or pre-determined definitions so that the data assesses consumers' views "in the context of real experiences." The report also leverages methodologies and software of Cognitive Edge, an organization that uses a science-based approach to organization decision making. The cost of a subscription for the U.S. market is $25,000 and allows unlimited online access to contents via MyKline.com, as well as direct access to the project team
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.